U.K. House of Commons committee demands more clinical-trial transparency

09/18/2013 | PharmaTimes (U.K.)

A House of Commons Science and Technology Committee report says too many clinical trials remain unregistered and unpublished, and the lack of transparency undermines public trust, slows medical progress and potentially puts patients at risk. The committee does not advocate uncontrolled release of patient-level data, but does urge stronger government action to facilitate sharing of raw clinical-trial data.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ